Roche Claims 'Other Options' If Illumina Deal Fails

Mar 06, 2012

NEW YORK (GenomeWeb News) – Roche Chairman Franz Humer today said that the firm has "other options" if its bid to acquire Illumina fails.

Humer's statement was part of prepared remarks made for Roche's annual general meeting, held today in Basel, Switzerland, where the firm is based.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Like Sears, But With Cells

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Infertile Mouse No More

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

PGD Growth Spurt

China is embracing preimplantation genetic diagnosis, Nature News reports.

This Week in PLOS

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep

28

Featured Webinar

Clinical Utility of Comprehensive and Fast Genomic Interpretation

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.

Main menu